In this podcast Nadia Harbeck discusses the primary analysis of the phase III KAITLIN study. This study analysed the invasive disease-free survival of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
Top
